Laboratory Co. of America Holdings (NYSE:LH) is expected to post earnings of $5.88 per share



Laboratory Co. of America” class=”companylogo”/>Brokers expect Laboratory Co. of America Holdings (NYSE: LH – Get Rating) to report earnings per share (EPS) of $5.88 for the current fiscal quarter, Zacks reports. Six analysts provided earnings estimates for Laboratory Co. of America, with the lowest EPS estimate of $4.46 and the highest estimate of $6.85. Laboratory Co. of America reported earnings of $8.79 per share in the same quarter last year, which would indicate a negative 33.1% year-over-year growth rate. The company is expected to release its next quarterly earnings report before the market opens on Monday, January 1.

Analysts expect Laboratory Co. of America to report annual earnings of $19.42 per share for the current fiscal year, with EPS estimates ranging from $18.18 to $20.64, according to Zacks. . For next year, analysts expect the company to post earnings of $18.11 per share, with EPS estimates ranging from $17.59 to $18.37. Zacks EPS averages are an average based on a survey of sell-side analysts who track Laboratory Co. of America.

Laboratory Co. of America (NYSE: LH – Get Rating) last released its results on Thursday, February 10. The medical research company reported earnings per share (EPS) of $6.77 for the quarter, beating the Zacks consensus estimate of $5.90 by $0.87. The company posted revenue of $4.06 billion in the quarter, versus analyst estimates of $3.93 billion. Laboratory Co. of America achieved a return on equity of 27.08% and a net margin of 14.75%. The company’s quarterly revenue was down 9.7% year over year. In the same quarter last year, the company posted EPS of $10.56.

A number of stock analysts have recently released reports on the company. Mizuho raised its price target on Laboratory Co. of America from $332.00 to $354.00 and gave the stock a “buy” rating in a Monday, Dec. 20 research note. Deutsche Bank Aktiengesellschaft downgraded Laboratory Co. of America from a “buy” rating to a “hold” rating and reduced its target price for the stock from $330.00 to $294.00 in a research note from the Friday January 28. Citigroup raised its price target on Laboratory Co. of America from $340.00 to $350.00 in a Friday, February 11 research report. Credit Suisse Group raised its price target on Laboratory Co. of America from $340.00 to $344.00 and gave the stock an “outperform” rating in a Friday, Feb. 11 research report. Finally, StockNews.com began covering Laboratory Co. of America in a research report on Thursday, March 31. They set a “buy” rating on the stock. Two investment analysts gave the stock a hold rating and nine gave the company a buy rating. According to data from MarketBeat, Laboratory Co. of America currently has an average rating of “Buy” and a consensus target price of $322.34.

In a similar vein, Executive Vice President Mark S. Schroeder sold 2,356 shares of Laboratory Co. of America in a trade dated Tuesday, March 29. The stock was sold at an average price of $277.11, for a total value of $652,871.16. The transaction was disclosed in a legal filing with the SEC, which is available via this hyperlink. Additionally, director R Sanders Williams sold 572 shares of Laboratory Co. of America in a trade dated Friday, March 25. The stock was sold at an average price of $272.98, for a total value of $156,144.56. The disclosure of this sale can be found here. Insiders sold a total of 3,749 shares of the company worth $1,031,367 in the past 90 days. Insiders own 0.31% of the shares of the company.

A number of hedge funds have recently bought and sold shares of LH. Kentucky Retirement Systems increased its position in shares of Laboratory Co. of America by 0.6% during the third quarter. Kentucky Retirement Systems now owns 5,721 shares of the medical research company valued at $1,610,000 after purchasing 35 additional shares during the period. Veritable LP increased its position in shares of Laboratory Co. of America by 2.4% during the third quarter. Veritable LP now owns 1,520 shares of the medical research company valued at $428,000 after buying 36 additional shares during the period. Condor Capital Management raised its position in shares of Laboratory Co. of America by 0.4% during the 4th quarter. Condor Capital Management now owns 9,835 shares of the medical research company valued at $3,090,000 after buying 37 additional shares during the period. Leuthold Group LLC increased its position in shares of Laboratory Co. of America by 0.3% during the third quarter. Leuthold Group LLC now owns 13,413 shares of the medical research company valued at $3,775,000 after purchasing 41 additional shares during the period. Finally, Valeo Financial Advisors LLC increased its stake in Laboratory Co. of America by 0.5% in the 4th quarter. Valeo Financial Advisors LLC now owns 8,241 shares of the medical research company valued at $2,589,000 after buying 41 additional shares in the last quarter. Institutional investors hold 88.22% of the company’s shares.

Shares of LH opened at $269.04 on Tuesday. The company has a market capitalization of $25.07 billion, a price-earnings ratio of 11.04 and a beta of 1.04. The company has a debt ratio of 0.54, a current ratio of 1.92 and a quick ratio of 1.77. The company has a fifty-day moving average of $270.49 and a 200-day moving average of $280.21. Laboratory Co. of America has a 1-year low of $254.46 and a 1-year high of $317.17.

The company also recently announced a quarterly dividend, which will be paid on Thursday, June 9. Shareholders of record on Thursday, May 19 will receive a dividend of $0.72 per share. This represents a dividend of $2.88 on an annualized basis and a dividend yield of 1.07%. The ex-dividend date is Wednesday, May 18.

Company Profile Laboratory Co. of America (Get a rating)

Laboratory Corporation of America Holdings operates as an independent clinical laboratory company worldwide. It operates in two segments, Labcorp Diagnostics (Dx) and Labcorp Drug Development (DD). It offers various tests, such as blood chemistry tests, urine tests, blood counts, thyroid tests, Pap tests, hemoglobin A1C and vitamin D products, prostate specific antigens, tests for sexually transmitted diseases, tests for hepatitis C, cultures and microbiology procedures, and alcohol and other drug tests.

Further reading

Get a Free Copy of Zacks’ Research Report on Laboratory Co. of America (LH)

For more information on Zacks Investment Research’s research offerings, visit Zacks.com

History and Earnings Estimates for Laboratory Co. of America (NYSE:LH)



Get news and reviews for Laboratory Co. of America Daily – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for Laboratory Co. of America and related companies with MarketBeat.com’s FREE daily email newsletter.

Previous Scientists discover differences in the interaction of T cells in tumor microenvironments
Next woman forced to pay 4.5 l for 'loan' | Bombay News